Skip to content

MDMA for addiction: all studies

Page 3 of 8: studies 21 to 30 of 76, newest first. Back to the MDMA for addiction overview

Research

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Annual Review of Psychology August 2, 2024 Keith Humphreys, Daniel Stjepanović, Wayne Hall et al. 18 citations

Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...

Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review

Psychoactives July 3, 2024 Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al. 4 citations

Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....

Chemical cousins with contrasting behavioural profiles: MDMA users and methamphetamine users differ in social-cognitive functions and aggression.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2024 Amelie Zacher, Josua Zimmermann, David M. Cole et al. 10 citations

Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") share structural-chemical similarities but have distinct psychotropic profiles due to specific neurochemical actions. Previous research has suggested that their impact on social cognitive functions and social behaviour may differ significantly, however, direct comparisons of METH and MDMA users...

Characterization of the Neurochemical and Behavioral Effects of the Phenethylamine 2-Cl-4,5-MDMA in Adolescent and Adult Male Rats.

The International Journal of Neuropsychopharmacology May 1, 2024 Gessica Piras, Cristina Cadoni, Francesca Caria et al. 3 citations

The proliferation of novel psychoactive substances (NPS) in the drug market raises concerns about uncertainty on their pharmacological profile and the health hazard linked to their use. Within the category of synthetic stimulant NPS, the phenethylamine 2-Cl-4,5-methylenedioxymethamphetamine (2-Cl-4,5-MDMA) has been linked to severe intoxication requiring hospitalization. Thereby, the...

DOI: 10.1093/ijnp/pyae016 (opens in new tab) Full text (opens in new tab) Serotonin Novel psychoactive substances Ultrasonic vocalizations #neuroscience +7

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Current Psychiatry Research and Reviews January 21, 2024 Payal Ghosh, Debjeet Sur 1 citation

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...

Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy.

Journal of psychopharmacology (Oxford, England) December 1, 2023 Brian J Gully, Erica Eaton, Christy Capone et al. 12 citations

Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the...

Striatal Iron Deposition in Recreational MDMA (Ecstasy) Users.

Biological psychiatry. Cognitive neuroscience and neuroimaging September 2023 Rebecca C Coray, Jatta Berberat, Josua Zimmermann et al.

The common club drug MDMA (also known as ecstasy) enhances mood, sensory perception, energy, sociability, and euphoria. While MDMA has been shown to produce neurotoxicity in animal models, research on its potential neurotoxic effects in humans is inconclusive and has focused primarily on the serotonin system. We investigated 34 regular, largely pure MDMA users for signs of premature...

Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders.

Metabolomics : Official journal of the Metabolomic Society August 2, 2023 Ross Van de Wetering, Jan A Vorster, Sophie Geyrhofer et al. 4 citations

Metabolomics produces vast quantities of data but determining which metabolites are the most relevant to the disease or disorder of interest can be challenging. This study sought to demonstrate how behavioral models of psychiatric disorders can be combined with metabolomics research to overcome this limitation. We designed a preclinical, untargeted metabolomics procedure, that focuses on the...

Modulation of Gut Microbiome in Ecstasy/MDMA-Induced Behavioral and Biochemical Impairment in Rats and Potential of Post-Treatment with Anacyclus pyrethrum L. Aqueous Extract to Mitigate Adverse Effects.

International Journal of Molecular Sciences May 22, 2023 Abdelmounaim Baslam, Abdelfatah Aitbaba, Asmae Lamrani Hanchi et al. 16 citations

The use of illicit substances continues to pose a substantial threat to global health, affecting millions of individuals annually. Evidence suggests the existence of a 'brain-gut axis' as the involving connection between the central nervous system and gut microbiome (GM). Dysbiosis of the GM has been associated with the pathogenesis of various chronic diseases, including metabolic, malignant,...

MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case study

March 10, 2023 Mika Turkia 1 citation preprint

In February 2023, Australia became the first country in the world to allow psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD). This may have left interested clinicians looking for practical examples of the use of MDMA. In the 1950s and 1960s, psychedelics were successfully utilized in the treatment of alcoholism. This case study, the...